companies

Qureight

Founded 2018
Employees 10+
Primary contact
Nine Hills Road
CB2 1GE Cambridge
United Kingdom
Links
https://qureight.com/
Diseases & Conditions
Sections
Technologies
Qureight uses cloud-based technology to assist in the structuring of image and paired clinical metadata in complex diseases. By structuring data in this way, it allows for the development of AI-based tools to understand diseases such as lung fibrosis, complex cancers and COVID-19. Moreover, it enables scientists to track disease progression and drug response, developing unique digital biomarkers for use in clinical trials.
Select clients: Takeda, Roche, Galapagos, AstraZeneca.
Founded 2018
Employees 10+
Primary contact
Nine Hills Road
CB2 1GE Cambridge
United Kingdom
Links
https://qureight.com/
Diseases & Conditions
Sections
Technologies

Funding 💰

Total £2M
Last round 🔗 £1.5M
Seed
February 1, 2022.
Select investors Playfair Capital, CMS Ventures, Ascension, Cambridge Angels, Meltwind Advisory

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Europe's first: In 2021, Qureight claims it became the first to integrate complex data sets and software algorithms across Europe. The work revealed the changes in blood distribution within the lungs in COVID-19 infection, which in turn opened the door to newer ways of treating patients by targeting the lung's blood supply.
  • Making clinical trials less expensive: Each Phase III pharmaceutical study in complex diseases can cost more than £200 million. Because Qureight's technology can develop unique digital biomarkers, it can significantly reduce the costs of bringing complex, life-saving drugs to market.
  • ISO13485 certified: In September 2022, the company announced that it had met the requirements to use our quality management system for the design of medical devices. 🔗

Quotes 💬

“
The world-leading clinical expertise of co-founders Dr Thillai and Dr Ruggiero has been crucial in Qureight's development of the world's only AI-powered platform dedicated to complex diseases. The technology offers an unrivalled integrated and secure solution for managing, analysing and sharing clinical data - and is set to transform the structuring of clinical trials and eventually the treatment of patients.
— Playfair Capital investor Jeevan Sunner 🔗
Last update: April 6, 2023